

Patrizia Castellani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5423497/publications.pdf>

Version: 2024-02-01

78
papers

4,569
citations

109264

35
h-index

98753

67
g-index

80
all docs

80
docs citations

80
times ranked

3709
citing authors

#	ARTICLE	IF	CITATIONS
1	Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. <i>International Journal of Cancer</i> , 2002, 102, 75-85.	2.3	321
2	The fibronectin isoform containing the ed-b oncofetal domain: A marker of angiogenesis. <i>International Journal of Cancer</i> , 1994, 59, 612-618.	2.3	283
3	Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. <i>Blood</i> , 2002, 99, 1659-1665.	0.6	262
4	Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. <i>Clinical Cancer Research</i> , 2003, 9, 571-9.	3.2	229
5	Selective targeted delivery of TNF α to tumor blood vessels. <i>Blood</i> , 2003, 102, 4384-4392.	0.6	218
6	Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells.. <i>Journal of Cell Biology</i> , 1987, 104, 595-600.	2.3	200
7	A High-Affinity Human Antibody That Targets Tumoral Blood Vessels. <i>Blood</i> , 1999, 94, 192-198.	0.6	191
8	Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. <i>International Journal of Cancer</i> , 1996, 68, 397-405.	2.3	145
9	Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. <i>International Journal of Cancer</i> , 1991, 47, 811-816.	2.3	138
10	Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. <i>International Journal of Cancer</i> , 1994, 59, 11-16.	2.3	136
11	Differentiation between High- and Low-Grade Astrocytoma Using a Human Recombinant Antibody to the Extra Domain-B of Fibronectin. <i>American Journal of Pathology</i> , 2002, 161, 1695-1700.	1.9	131
12	Transformed human cells release different fibronectin variants than do normal cells.. <i>Journal of Cell Biology</i> , 1986, 103, 1671-1677.	2.3	126
13	Transforming growth factor- β 2 regulates the splicing pattern of fibronectin messenger RNA precursor. <i>FEBS Letters</i> , 1990, 261, 175-178.	1.3	119
14	Molecular Imaging of Atherosclerotic Plaques Using a Human Antibody Against the Extra-Domain B of Fibronectin. <i>Circulation Research</i> , 2004, 95, 1225-1233.	2.0	116
15	Identification of a Glioblastoma-Associated Tenascin-C Isoform by a High Affinity Recombinant Antibody. <i>American Journal of Pathology</i> , 1999, 154, 1345-1352.	1.9	104
16	DAMPs and inflammatory processes: the role of redox in the different outcomes. <i>Journal of Leukocyte Biology</i> , 2009, 86, 549-555.	1.5	96
17	Targeted Delivery of Tumor Necrosis Factor- α to Tumor Vessels Induces a Therapeutic T Cell-Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin. <i>Clinical Cancer Research</i> , 2006, 12, 2575-2582.	3.2	85
18	Redox Remodeling Allows and Controls B-Cell Activation and Differentiation. <i>Antioxidants and Redox Signaling</i> , 2010, 13, 1145-1155.	2.5	83

#	ARTICLE	IF	CITATIONS
19	Elution of fibronectin proteolytic fragments from a hydroxyapatite chromatography column. A simple procedure for the purification of fibronectin domains. <i>FEBS Journal</i> , 1985, 146, 571-579.	0.2	80
20	CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory. <i>Clinical Cancer Research</i> , 2006, 12, 3435-3443.	3.2	79
21	The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants. <i>International Journal of Cancer</i> , 2008, 123, 1770-1778.	2.3	73
22	TLR Costimulation Causes Oxidative Stress with Unbalance of Proinflammatory and Anti-Inflammatory Cytokine Production. <i>Journal of Immunology</i> , 2014, 192, 5373-5381.	0.4	73
23	Large-scale procedure for the purification of fibronectin domains. <i>Analytical Biochemistry</i> , 1986, 155, 335-345.	1.1	66
24	The thiol redox state of lymphoid organs is modified by immunization: Role of different immune cell populations. <i>European Journal of Immunology</i> , 2008, 38, 2419-2425.	1.6	66
25	High-Mobility Group Box 1 Release and Redox Regulation Accompany Regeneration and Remodeling of Skeletal Muscle. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 2161-2174.	2.5	61
26	Inflammation, DAMPs, Tumor Development, and Progression: A Vicious Circle Orchestrated by Redox Signaling. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 1086-1097.	2.5	61
27	Lack of specificity of endoglin expression for tumor blood vessels. <i>International Journal of Cancer</i> , 2001, 94, 579-585.	2.3	59
28	Expression of tenascin and of the ED-B containing oncofetal fibronectin isoform in human cancer. <i>Cell Differentiation and Development</i> , 1990, 32, 401-408.	0.4	51
29	Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNF- α . <i>International Journal of Cancer</i> , 2010, 127, 101-110.	2.3	50
30	Characterization of synovial fluid fibronectin from patients with rheumatic inflammatory diseases and healthy subjects. <i>Arthritis and Rheumatism</i> , 1984, 27, 913-921.	6.7	49
31	Identification of a novel cell binding site of periostin involved in tumour growth. <i>European Journal of Cancer</i> , 2011, 47, 2221-2229.	1.3	48
32	Therapy-induced antitumor vaccination by targeting tumor necrosis factor- α to tumor vessels in combination with melphalan. <i>European Journal of Immunology</i> , 2007, 37, 3381-3392.	1.6	41
33	The Cystine/Cysteine Cycle and GSH Are Independent and Crucial Antioxidant Systems in Malignant Melanoma Cells and Represent Druggable Targets. <i>Antioxidants and Redox Signaling</i> , 2011, 15, 2439-2453.	2.5	41
34	Cell-Cycle Dependent Alternative Splicing of the Tenascin Primary Transcript. <i>Cell Adhesion and Communication</i> , 1994, 1, 307-317.	1.7	40
35	Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance. <i>Cell Death and Disease</i> , 2016, 7, e2304-e2304.	2.7	40
36	A pilot pharmacokinetic and immunoscintigraphic study with the technetium-99m-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors. <i>Cancer</i> , 1997, 80, 2484-2489.	2.0	30

#	ARTICLE	IF	CITATIONS
37	Redox remodeling: a candidate regulator of HMGB1 function in injured skeletal muscle. <i>Annals of the New York Academy of Sciences</i> , 2010, 1209, 83-90.	1.8	29
38	Increased myocardial 18F-FDG uptake as a marker of Doxorubicin-induced oxidative stress. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 2183-2194.	1.4	29
39	Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions. <i>International Immunology</i> , 2009, 21, 655-665.	1.8	28
40	CIITA-driven MHC-II positive tumor cells: Preventive vaccines and superior generators of antitumor CD4 ⁺ T lymphocytes for immunotherapy. <i>International Journal of Cancer</i> , 2010, 127, 1614-1624.	2.3	28
41	Tenascin distribution in human brain tumours. <i>Acta Neurochirurgica</i> , 1995, 136, 44-50.	0.9	27
42	A functional monoclonal antibody recognizing the human alpha 1 integrin domain. <i>Tissue Antigens</i> , 1996, 48, 47-51.	1.0	27
43	A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B. <i>International Journal of Cancer</i> , 2009, 125, 751-758.	2.3	27
44	Rebalancing expression of HMGB1 redox isoforms to counteract muscular dystrophy. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	26
45	Obligatory role of endoplasmic reticulum in brain FDG uptake. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1184-1196.	3.3	24
46	DNA-binding domains of human plasma fibronectin. pH and calcium ion modulation of fibronectin binding to DNA and heparin. <i>FEBS Journal</i> , 1986, 154, 533-538.	0.2	23
47	Fibronectin concentrations in pleural effusions of patients with malignant and non-malignant diseases. <i>Cancer Letters</i> , 1984, 22, 1-9.	3.2	22
48	Preparation of Phage Antibodies to the ED-A Domain of Human Fibronectin. <i>Experimental Cell Research</i> , 1998, 240, 244-251.	1.2	22
49	Alternative Splicing of the Angiogenesis Associated Extra-Domain B of Fibronectin Regulates the Accessibility of the B-C Loop of the Type III Repeat 8. <i>PLoS ONE</i> , 2010, 5, e9145.	1.1	18
50	Expression of extradomain-B-containing fibronectin in subretinal choroidal neovascular membranes. <i>American Journal of Ophthalmology</i> , 2003, 135, 7-13.	1.7	16
51	The Angiogenesis Marker ED-B+ Fibronectin Isoform in Intracranial Meningiomas. <i>Acta Neurochirurgica</i> , 2000, 142, 277-282.	0.9	15
52	Mechanisms underlying the predictive power of high skeletal muscle uptake of FDG in amyotrophic lateral sclerosis. <i>EJNMMI Research</i> , 2020, 10, 76.	1.1	15
53	Structural differences in the cell binding region of human fibronectin molecules isolated from cultured normal and tumor-derived human cells. <i>FEBS Letters</i> , 1985, 192, 71-74.	1.3	14
54	A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 368-378.e13.	1.5	14

#	ARTICLE	IF	CITATIONS
55	Schedule-dependent therapeutic efficacy of L19m TNF α and melphalan combined with gemcitabine. <i>Cancer Medicine</i> , 2013, 2, 478-487.	1.3	13
56	FDG uptake tracks the oxidative damage in diabetic skeletal muscle: An experimental study. <i>Molecular Metabolism</i> , 2020, 31, 98-108.	3.0	13
57	The pharmacologic inhibition of the xc- antioxidant system improves the antitumor efficacy of COX inhibitors in the in vivo model of 3-MCA tumorigenesis. <i>Carcinogenesis</i> , 2013, 34, 620-626.	1.3	12
58	Expression of N-CAM by Human Renal Cell Carcinomas Correlates with Growth Rate and Adhesive Properties. <i>Experimental Cell Research</i> , 1994, 214, 499-509.	1.2	11
59	Iatrogenic dissection of the portal vein during TIPS procedure. <i>European Radiology</i> , 2000, 10, 930-934.	2.3	11
60	Occurrence of a Glioblastoma-associated Tenascin-C Isoform in Cerebral Cavernomas and Neighboring Vessels. <i>Neurosurgery</i> , 2002, 50, 838-842.	0.6	11
61	CXCR4 engagement triggers CD47 internalization and antitumor immunization in a mouse model of mesothelioma. <i>EMBO Molecular Medicine</i> , 2021, 13, e12344.	3.3	11
62	The Role of Endoplasmic Reticulum in the Differential Endurance against Redox Stress in Cortical and Spinal Astrocytes from the Newborn SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. <i>Antioxidants</i> , 2021, 10, 1392.	2.2	10
63	Increased plasma fibronectin concentrations in tumor bearing mice. <i>Cancer Letters</i> , 1983, 21, 117-123.	3.2	9
64	Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report. <i>BMC Biotechnology</i> , 2011, 11, 104.	1.7	9
65	Restoring microenvironmental redox and pH homeostasis inhibits neoplastic cell growth and migration: therapeutic efficacy of esomeprazole plus sulfasalazine on 3-MCA-induced sarcoma. <i>Oncotarget</i> , 2017, 8, 67482-67496.	0.8	9
66	Fibronectin concentration in the plasma of patients with malignant and benign breast disease. <i>Cancer Letters</i> , 1986, 33, 317-323.	3.2	8
67	The Elusive Link Between Cancer FDG Uptake and Glycolytic Flux Explains the Preserved Diagnostic Accuracy of PET/CT in Diabetes. <i>Translational Oncology</i> , 2020, 13, 100752.	1.7	8
68	Distribution of tenascin in human malignant gliomas is not related to cell proliferation.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 62, 290-291.	0.9	6
69	Use of Uteroglobin for the Engineering of Polyvalent, Polyspecific Fusion Proteins. <i>Journal of Biological Chemistry</i> , 2009, 284, 26646-26654.	1.6	6
70	¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography Tracks the Heterogeneous Brain Susceptibility to the Hyperglycemia-Related Redox Stress. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8154.	1.8	6
71	Lack of sialic acid in synovial fluid fibronectin. <i>FEBS Letters</i> , 1984, 171, 285-288.	1.3	5
72	Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models. <i>Cancer Medicine</i> , 2021, 11, 183.	1.3	4

#	ARTICLE	IF	CITATIONS
73	Oncofetal matrix glycoproteins in cerebral arteriovenous malformations and neighbouring vessels. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 68, 101-102.	0.9	3
74	Tenascin-C in astrocytic tumors. World Neurosurgery, 2002, 57, 286.	1.3	3
75	Accumulation of oncofetal fibronectin in the vessels of anaplastic meningiomas. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 412-413.	0.9	2
76	Fibronectin Concentration in Plasma of Patients with Breast Cancer. Annals of the New York Academy of Sciences, 1986, 464, 454-456.	1.8	1
77	SAT0001â€¦Cryopyrin Associated Periodic Syndromes (CAPS): Investigations on Knock-In Mouse Model to Exploit Novel Approaches for the Modulation of the NLRP3 Inflammasome. Annals of the Rheumatic Diseases, 2015, 74, 650.1-650.	0.5	0
78	OP0106â€¦A NOVEL KNOCK-IN MOUSE MODEL OF CAPS THAT DEVELOPS AMYLOIDOSIS: THERAPEUTIC EFFICACY OF PROTON PUMP INHIBITORS. , 2019, , .		0